



Medical University of Graz


# Tryptophan, Kynurenone and Quinolinic Acid

-

## What are they good for?

**Nicolas Verheyen, MD**  
**Department of Cardiology**  
**Medical University of Graz Austria**

[nicolas.verheyen@medunigraz.at](mailto:nicolas.verheyen@medunigraz.at)




# Tryptophan-kynurenine pathway: Acceleration upon Inflammation

IFN- $\gamma$ , IFN- $\beta$ , IFN- $\alpha$ , TNF- $\alpha$  ...


Indolamin-2,3-dioxygenase (IDO)

Kynureninase  
3-hydroxy-anthranoate  
3,4-dioxygenase


Tryptophan



Kynurenine



Quinolinic acid



„Neurotoxin, gliotoxin, proinflammatory mediator, prooxidant molecule“


# Activation of NAD(P)H Oxidase by tryptophan-derived 3-hydroxykynurenine Accelerates Endothelial Apoptosis and Dysfunction *In Vivo*





Medical University of Graz

Qiongxin Wang, Miao Zhang, Ye Ding, Qilong Wang, Wencheng Zhang, Ping Song, and Ming-Hui Zou

Section of Molecular Medicine, Dep Molecular Biology, University of Okla USA



## Quinolinic acid induces superoxide anion production in rat striatal cells



Apoptosis  
in  
vivo  
NAD(P)H oxidase-

Maldonado et al. *Journal of Neuroscience Research* 88:620–629 (2010)

# Development of a liquid chromatography–mass spectrometry method for the determination of the neurotoxic quinolinic acid in human serum

Andreas Meinitzer <sup>a,\*</sup>, Andreas Tomaschitz <sup>b,c</sup>, Stefan Pilz <sup>d</sup>, Manfred Truber <sup>a</sup>, Gabriele Zechner <sup>a</sup>, Martin Gaksch <sup>d</sup>, Barbara Prietl <sup>d</sup>, Gerlies Treiber <sup>d</sup>, Michaela Schwarz <sup>e</sup>, Andreas Baranyi <sup>f</sup>

<sup>a</sup> Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Graz, Austria

<sup>b</sup> Department of Cardiology, Medical University of Graz, Graz, Austria

<sup>c</sup> Specialist Clinic for Rehabilitation PV Bad Aussee, Bad Aussee, Austria

<sup>d</sup> Department of Internal Medicine, Division of Endocrinology and Metabolism, Medical University of Graz, Graz, Austria

<sup>e</sup> Division of Surgical Research, Department of Surgery, Medical University of Graz, Graz, Austria

<sup>f</sup> Department of Psychiatry, Medical University of Graz, Graz, Austria

Characteristics of the quinolinic acid method.

|   | Quinolinic acid |      |
|---|-----------------|------|
| Working range [nmol/L]                            | 50–5000         |      |
| Calibration curve                                 |                 |      |
| Slope   | 0.03725         |      |
| Intercept   | 0.00224         |      |
| Correlation r <sup>2</sup>                        | 0.9998          |      |
| Intra-day precision n = 6                         | Low             | High |
| Mean [nmol/L]                                     | 225             | 725  |
| SD [nmol/L]                                       | 10.2            | 8.5  |
| Coefficient of variation [%]                      | 4.5             | 1.2  |
| Inter-day precision n = 20                        |                 |      |
| Mean [nmol/L]                                     | 229             | 752  |
| SD [nmol/L]                                       | 17.0            | 47.3 |
| Inter-day variability [%]                         | 7.2             | 6.3  |
| Recovery (mean extraction efficiency)<br>[% ± SD] | 95.0 ± 7.7      |      |
| Limit of quantification                           |                 |      |
| (LOQ) [nmol/L]                                    | 50              |      |
| SD [nmol/L]                                       | 4.7             |      |
| Coefficient of variation [%]                      | 9.3             |      |
| Limit of detection (LOD) [nmol/L]                 | 15              |      |
| 3-fold SD of the baseline noise                   |                 |      |
| Stability in the matrix tested                    | 2 days          |      |

Patients characteristics and quinolinic acid concentration.

|                                      |             |
|--------------------------------------|-------------|
| Number of patients                   | 50          |
| Females [%]                          | 64          |
| Age [yrs]                            | 31 ± 8      |
| Body mass index [kg/m <sup>2</sup> ] | 23.3 ± 4.3  |
| Systolic blood pressure [mm Hg]      | 129 ± 15    |
| Diastolic blood pressure [mm Hg]     | 84 ± 10     |
| Glucose [mmol/L]                     | 4.89 ± 0.92 |
| HDL-cholesterol [mmol/L]             | 1.84 ± 0.37 |
| LDL-cholesterol [mmol/L]             | 2.46 ± 0.57 |
| Triglycerides [mmol/L]               | 1.08 ± 0.49 |
| Quinolinic acid [nmol/L]             | 350 ± 167   |

Continuous variables are presented as means ± standard deviation (SD).



STUDY PROTOCOL

Open Access

# Effect of eplerenone on parathyroid hormone levels in patients with primary hyperparathyroidism: a randomized, double-blind, placebo-controlled trial

Andreas Tomaschitz<sup>1\*†</sup>, Astrid Fahrleitner-Pammer<sup>2</sup>, Burkert Pieske<sup>1</sup>, Nicolas Verheyen<sup>1</sup>, Karin Amrein<sup>2</sup>, Eberhard Ritz<sup>3</sup>, Katharina Kienreich<sup>2</sup>, Jörg H Horina<sup>4</sup>, Albrecht Schmidt<sup>1</sup>, Elisabeth Kraigher-Krainer<sup>1</sup>, Caterina Colantonio<sup>1</sup>, Andreas Meinitzer<sup>5</sup> and Stefan Pilz<sup>2,6\*†</sup>

## In/Exclusion criteria:


- Primary hyperparathyroidism (biochemical diagnosis)
- Age > 18
- no acute illness

## Blood sampling and storage at -80 °C

- Tryptophan
- Kynurenone
- Quinolinic acid

## 24-hour ambulatory blood pressure monitoring

## Echocardiography



Effect of eplerenone on parathyroid hormone levels in patients with primary hyperparathyroidism: a randomized, double-blind, placebo-controlled trial



Medical University of Graz

## Baseline characteristics

|  |              |
|--|--------------|
| Age, years   | 67 +/- 10    |
| Females, n (%)   | 104 (78%)    |
| Body mass index, kg/m <sup>2</sup>                                       | 27 +/- 5     |
| Smokers, n (%)   | 50 (38%)     |
| Estimated glomerular filtration rate (CKDEPI), mL/min/1.73m <sup>2</sup> | 77 +/- 16    |
| Total cholesterol, mg/dL   | 202 +/- 43   |
| HbA1c, mmol/mol  | 37 (35 – 40) |
| GFR, ml/min/m <sup>2</sup>   | 78 +/- 16    |
| Total cholesterol, mg/dL   | 202 +/- 43   |


## Tryptophan-kynurenine pathway

|                         |                 |
|-------------------------|-----------------|
| Tryptophan, µmol/L      | 55.9 +/- 10.0   |
| Kynurene, µmol/L        | 2.8 +/- 0.8     |
| Quinolinic acid, nmol/L | 497 (406 – 633) |


## Cardiovascular parameters

|   |                   |
|---|-------------------|
| Left ventricular ejection fraction, %         | 63 (59 – 68)      |
| E/e' (average)                                | 10.1 (8.1 – 12.9) |
| e', m/s (average)                             | 7.1 +/- 2.3       |
| Left ventricular mass index, g/m <sup>2</sup> | 102 (81 – 123)    |
| Left ventricular hypertrophy, n (%)           | 70 (45 %)         |
| Left atrial volume index, ml/m <sup>2</sup>   | 30 (23 – 36)      |
| Left atrial dilatation, n (%)                 | 83 (54%)          |
| Mean 24h systolic BP, mmHg                    | 122 +/- 11        |
| Mean 24h diastolic BP, mmHg                   | 73 +/- 7          |
| Mean nighttime systolic BP, mmHg              | 113 +/- 14        |
| Mean nighttime diastolic BP, mmHg             | 65 +/- 9          |
| Arterial hypertension, n (%)                  | 97 (73%)          |
| Antihypertensive medication , n (%)           | 85 (64%)          |

## High tryptophan → high kynurenine?



## High kynurenine → high quinolinic acid?





## Determinants of tryptophan, kynurenone and quinolinic acid in multivariate linear regression analyses

|                           | Tryptophan |        | Kynurenone |        | Quinolinic acid |        |
|---------------------------|------------|--------|------------|--------|-----------------|--------|
|                           | $\beta$    | P      | $\beta$    | P      | $\beta$         | P      |
| <b>Age</b>                |            | ns     |            | ns     | 0.180           | 0.003  |
| <b>Gender</b>             | 0.304      | <0.001 | 0.131      | 0.045  |                 | ns     |
| <b>BMI</b>                | 0.187      | 0.040  |            | ns     |                 | ns     |
| <b>eGFR (CKDEPI)</b>      |            | ns     | -0.525     | <0.001 | -0.275          | <0.001 |
| <b>Total cholesterol</b>  | 0.147      | 0.072  | -0.163     | 0.012  |                 | ns     |
| <b>Diabetes mellitus</b>  |            | ns     |            | ns     |                 | ns     |
| <b>C-reactive protein</b> |            | ns     | 0.167      | 0.017  | 0.154           | 0.007  |
| <b>Tryptophan</b>         | -          |        | 0.452      | <0.001 | -0.051          | 0.403  |
| <b>Kynurenone</b>         | -          |        | -          |        | 0.554           | <0.001 |

Effect of eplerenone on parathyroid hormone levels in patients with primary hyperparathyroidism: a randomized, double-blind, placebo-controlled trial




Medical University of Graz


# Left ventricular hypertrophy

## Kynurenine



T-test



## Quinolinic acid



Analysis of Covariance



Effect of eplerenone on parathyroid hormone levels in patients with primary hyperparathyroidism: a randomized, double-blind, placebo-controlled trial




Medical University of Graz


## Left atrial dilatation

### Kynurenine



T-test



### Quinolinic acid



Analysis of Covariance



# Conclusions



Medical University of Graz

- Quinolinic acid levels are not independently related with tryptophan levels
- Independent correlation with cardiac structure and function
- Cause-effect relationship unclear
  - direct effects?
  - epiphenomenon 3-OH kynurenone?
- Mechanisms to be elucidated

## Acknowledgments

Andreas Meinitzer

Andreas Tomaschitz

Stefan Pilz

Helmut Brussee

Martin Gaksch



Medical University of Graz



Winfried März

Burkert Pieske

Evgeny Belyavskiy



Austrian Society for Bone and Mineral Research



Austrian National Bank



Inselspital Bern

Martin Grübler